SEPTIN6

Across TCGA pan-cancer cohorts, SEPTIN6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SEPTIN6 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEPTIN6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SEPTIN6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SEPTIN6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.874	0.648	<.001	57	view →
HNSC	DFS	Median	All	0.907	0.994	.004	8	view →
LUAD	DFS	Tertile	All	0.761	0.423	.014	5	view →
UCEC	DFS	Tertile	III,IV	0.529	1.000	.049	4	view →
CCRCC	OS	Median	II,III,IV	1.000	0.499	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SEPTIN6–PDAC (DFS)

Open the PDAC breakdown →